FDA Office of Clinical Pharmacology Announces Availability of 2019 Annual Reports

FDA Office of Clinical Pharmacology Announces Availability of 2019 Annual Reports

The Food and Drug Administration (FDA), Office of Clinical Pharmacology (OCP) announces the availability of the 2019 OCP and Division of Applied Regulatory Science (DARS) Annual Reports. OCP is a dynamic, purpose-driven organization dedicated to promoting and protecting global public health through the application of clinical pharmacology and translational medicine principles. OCP’s mission is to play a pivotal role in advancing development of innovative new medicines by applying state-of-the-art scientific principles; and promote therapeutic optimization and individualization through best practices in research, policy development, and drug evaluation throughout the product lifecycle. The 2019 OCP and DARS Annual Reports highlight OCP’s important work towards a vision of improving public health by building and translating knowledge of drug-response into patient-centered regulatory decisions of the highest quality.

DARS is a multidisciplinary research division of OCP that performs mission-critical applied research and review across the translational research spectrum, including in vitro and in vivo laboratory research, in silico computational modeling and informatics, and integrated clinical research covering clinical pharmacology, experimental medicine, and postmarket analyses.

Learn more about OCP’s diverse functional responsibilities, value-focused culture, 2019 achievements, and 2020 outlook found in the reports at the following links: 2019 OCP Annual Report: https://go.usa.gov/xdKbc, 2019 DARS Annual Report: https://go.usa.gov/xdKbQ. Past OCP annual reports can be found at: https://go.usa.gov/xd9fu.